Cardiac Science Announces Third Quart...(Net income attributable to n...),Health

Date:11/9/2009

Net income attributable to noncontrolling interests (135) -0.3% (86) -0.2% ---- ---- --- ---- Net income (loss) attributable to Cardiac Science Corporation $(66,546) -171.1% $2,478 4.6% ======== ====== ====== === Net income (loss) per share attributable to Cardiac Science Corporation: Basic $(2.85) $0.11 Diluted $(2.85) $0.11 Weighted average shares outstanding: Basic 23,368,778 22,892,161 Diluted 23,368,778 23,413,042 Cardiac Science Corporation and Subsidiaries Condensed Consolidated Statements of Operations (unaudited) (in thousands, except share and per share amounts) Nine Months Ended September 30, ----------------------- 2009 2008 ---- ---- $ % $ % --- --- --- --- Revenues: Cardiac monitoring products $40,151 35.0% $48,613 31.3% Defibrillation products 61,413 53.6% 92,371 59.6% ------ ---- ------ ---- Total product revenues 101,564 88.6% 140,984 90.9% Service 13,098 11.4% 14,113 9.1% ------ ---- ------ --- Total revenues 114,662 100.0% 155,097 100.0% -------
'/>"/>

SOURCE Cardiac Science Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Related medicine technology :

1. Personalized Medicine - The Genomic Revolution in Cardiac Care
2. FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
3. Signalife Completes Testing of Modules for Holter and Intra-Cardiac Monitor
4. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
5. Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery
6. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
7. Do-It-Yourself Cardiac Bypass Surgery: All You Need is Walking Shoes
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
10. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
11. Study Finds PCI Safe, Effective Despite Off-Site Cardiac Surgery